Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak(Roswell Park Comprehensive Cancer Center), Melinda L. Telli(Stanford University), Carey K. Anders(Duke University), Gerburg M. Wulf(Beth Israel Deaconess Medical Center), Antoinette R. Tan(Wake Forest University), Georgia A. McCann(The Ohio State University Wexner Medical Center), Andres Forero(University of Alabama at Birmingham), Nathan Buerstatte(Massachusetts General Hospital), John K. Erban(Tufts University), Yinghui Zhou(Soochow University), Sara M. Tolaney(Harvard University), Patrick M. Dillon(University of Virginia), Lee S. Schwartzberg(Renown Health), Corrine Zarwan(Beth Israel Deaconess Medical Center), Julie R. Graham(Tesaro (United States)), Monica Mita(Novartis (Switzerland)), Bruce J. Dezube(Xilio Therapeutics (United States)), Filipa Lynce(Institut Claudius Regaud), Sujata Arora(Tesaro (United States)), Andrea E. Wahner-Hendrickson(Mayo Clinic)
Cited by 446
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k